DiaSorin (DIA) investor relations material

Strategic direction and market positioning

• Five-year plan focuses on specialty leadership in immunodiagnostics, molecular diagnostics, and life sciences, emphasizing innovation, automation, and global expansion, with U.S. revenues now at 50% due to the Luminex acquisition and targeting further growth.

• Specialist positioning targets high-growth areas such as autoimmunity, IBD, hypertension, and women's health, while avoiding less differentiated segments like cancer and diabetes.

• Addresses macro healthcare trends including demographic shifts, lab consolidation, decentralization, value-based care, and precision medicine.

• Created new business opportunities in life sciences, expanding reach among academic, biopharma, and pharmaceutical partners.

• Strengthens partnerships and business development through licensed technologies and a strong partner ecosystem.

Financial guidance and capital allocation

• Revenue growth guidance of 5%-6% for 2026, accelerating to 6%-8% CAGR through 2030, with adjusted EBITDA margin targeted to expand to 34%-35% by 2030.

• Immunodiagnostics expected to grow mid-single digits, molecular diagnostics at high teens post-2026, and licensed technologies contributing 10% of revenues by 2030.

• Free cash flow generation of approximately €1 billion expected from 2027–2030, with capital allocation prioritizing organic growth, progressive dividends, targeted M&A, and selective share buybacks.

• By 2030, North America is projected to account for 60% of revenues, with molecular diagnostics nearly doubling its revenue share.

• Financials are presented at constant exchange rates for comparability.

Innovation, product pipeline, and operational execution

• Commitment to launch over 20 new specialty immunodiagnostic assays and new molecular platforms by 2030, with autoimmunity and high clinical value areas as major focuses.

• LIAISON NES targets over $150 million in U.S. sales, and LIAISON PLEX multiplexing to exceed €180 million by 2030, supporting rapid, automated, and customizable testing.

• Differentiation through customizable panels (PLEX), rapid point-of-care solutions (NES), and specialty tests in GI, TB, hypertension, and MeMed for antibiotic stewardship.

• Automation and digitalization drive operational efficiency, with plant consolidation, AI-enabled process optimization, and new analyzers like LIAISON XL.

• ESG priorities include CO2 reduction, diversity and inclusion, STEM education, and linking executive pay to ESG targets, with 100% employee D&I training and >20 high clinical value assays by 2030.